TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22410401

Group type: EXPERIMENTAL
Intervention: Aluminium oxide sandblasting (AO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fine diamond bur (FDB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Medium diamond bur (MDB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Coarse diamond bur (CDB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrophilic adhesive (Adper Single Bond 2, 3M ESPE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrophobic adhesive (Scotchbond Multi‐Purpose Plus, 3M ESPE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surface roughness (SR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surface area (SA)
Number of subjects: 50
Study: 20405138

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clonidine + Arginine (combined)
Number of subjects: 50
Study: 18212033

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Number of subjects: 43
Study: 15723993

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (10 minutes of ischemia and 10 minutes of reperfusion prior to Pringle maneuver)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pringle maneuver
Number of subjects: 75

Group type: COMPARATOR
Intervention: No Pringle maneuver
Number of subjects: 75
Study: 14967189

Group type: EXPERIMENTAL
Intervention: Nicotine-patch therapy for 8 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nicotine-patch therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 11137103

Group type: EXPERIMENTAL
Intervention: Lipid variables including total cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, triglycerides, and LDL/HDL ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined lipid variables
Number of subjects: 0
Study: 9272748

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide treatment
Number of subjects: 28
Study: 8059505

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 0
Study: 3066967

Group type: EXPERIMENTAL
Intervention: Ryodipine (30 mg single dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine (single dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ryodipine (150 mg/day for a short period)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ryodipine (150 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ryodipine (250 mg/day)
Number of subjects: 23
Study: 31246277

Group type: EXPERIMENTAL
Intervention: API-AI regimen
Number of subjects: 106
Study: 31209710

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided local insulin injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single injection of 40 mg methylprednisolone acetate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Steroid injection followed by insulin injection twice after 2 and 4 weeks
Number of subjects: 60
Study: 27468867

Group type: EXPERIMENTAL
Intervention: Urinary cell free DNA testing
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: T790M+ group
Number of subjects: 150
Study: 26233572

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233mg zinc gluconate containing 30mg zinc)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23510646

Group type: EXPERIMENTAL
Intervention: Intervention group (Teamplay parenting program)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 21615456

Group type: EXPERIMENTAL
Intervention: pMDI and AeroChamber Plus™
Number of subjects: 12

Group type: COMPARATOR
Intervention: pMDI alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: pMDI and charcoal ingestion
Number of subjects: 12
Study: 19110788

Group type: EXPERIMENTAL
Intervention: Simple stenting strategy (MV group)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Complex stenting strategy (MV+SB group)
Number of subjects: 413
Study: 16869483

Group type: EXPERIMENTAL
Intervention: Theta-beta training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SCP training
Number of subjects: 38
Study: 12929098

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA) and adjunctive balloon angioplasty (PTCA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA) alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-pressure strategy after RA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 56
Study: 11138997

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 9084600

Group type: EXPERIMENTAL
Intervention: New learning condition with feedback (correct/incorrect moves)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free selection task (no feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive movement of the same finger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline condition (pacing tones and auditory feedback, no movements)
Number of subjects: 0
Study: 8471818

Group type: EXPERIMENTAL
Intervention: 3 g/day n‐3 fatty acids
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 4.5 g/day n‐3 fatty acids
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids treatment
Number of subjects: 9
Study: 3899152

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg i.v.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31604574

Group type: EXPERIMENTAL
Intervention: Integration of radiomics and clinical models
Number of subjects: 295

Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 295

Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 295
Study: 27977518

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Modified Fitness Counts (mFC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 48
Study: 25909465

Group type: EXPERIMENTAL
Intervention: Elder Tree (information and communication technology) for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual sources of information and communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elder Tree
Number of subjects: 0
Study: 23608592

Group type: COMPARATOR
Intervention: PVI+LL
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: PVI+GP
Number of subjects: 264
Study: 20674982

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 177
Study: 19644031

Group type: EXPERIMENTAL
Intervention: Moderate exercise (ME) at 12% O2 for 30 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate exercise (ME) at 15% O2 for 30 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strenuous exercise (SE) at 21% O2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Moderate exercise (ME) at 21% O2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resting at 12% O2 for 30 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resting at 15% O2 for 30 min
Number of subjects: 15
Study: 17080448

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced form of CBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative cognitive-affective therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted and unassisted self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New treatment approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment modeling
Number of subjects: 0
Study: 15631318

Group type: EXPERIMENTAL
Intervention: omeprazole alone (O)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: omeprazole and amoxicillin (OA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: omeprazole, amoxicillin and tinidazole (OAT)
Number of subjects: 43
Study: 11414346

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) coping skills training
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Random treatment assignment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prospective matching
Number of subjects: 250
Study: 9715740

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (10 g day-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (glucose polymers)
Number of subjects: 10
Study: 7839282

Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate regimen (loading dose of 14 g: 4 g i.v. and 10 g IM, followed by 5 g 4-hourly)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate regimen (loading dose of 6 g i.v., followed by maintenance infusion of 2 g/h)
Number of subjects: 17
Study: 3402353

Group type: EXPERIMENTAL
Intervention: Urapidil 25 mg intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30561313

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole preventive therapy
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Antibacterial drugs (general)
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Penicillins
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Sulfonamides
Number of subjects: 2152
Study: 28097295

Group type: EXPERIMENTAL
Intervention: Systemic β-blocker use
Number of subjects: 8063

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 8063

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 8063

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 8063

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 8063
Study: 25730540

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine cream (SSD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water-soluble polyantimicrobial gel (BWG)
Number of subjects: 8
Study: 23261228

Group type: EXPERIMENTAL
Intervention: Sulindac 150mg bid for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo bid for 6 months
Number of subjects: 61
Study: 20656508

Group type: EXPERIMENTAL
Intervention: Actual weight-based dose of IV t-PA (administered dose divided by actual weight, capped at 100 kg)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Actual weight-based dose of IV t-PA
Number of subjects: 311
Study: 19337705

Group type: EXPERIMENTAL
Intervention: Ex-PRESS implantation under a scleral flap
Number of subjects: 78

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 78
Study: 17299064

Group type: EXPERIMENTAL
Intervention: Pio (7.5 mg/d) + Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Number of subjects: 38
Study: 15159232

Group type: COMPARATOR
Intervention: WB (12 g fiber/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: WBRS (12 g WB fiber/d plus 22 g RS/d)
Number of subjects: 20
Study: 12743147

Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) therapy group
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control arm (no SE)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Both groups (SE therapy and control)
Number of subjects: 235
Study: 10426704

Group type: EXPERIMENTAL
Intervention: High-vegetable diet (490 g/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-vegetable diet supplemented with beta-carotene (6 mg/d) and lutein (9 mg/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-vegetable diet (130 g/d)
Number of subjects: 54
Study: 7750429

Group type: EXPERIMENTAL
Intervention: Potassium citrate (120 mmol daily for 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Potassium chloride (120 mmol daily for 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2180461

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (n = 41)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte (n = 38)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 189
Study: 535840

Group type: EXPERIMENTAL
Intervention: Frubiase Calcium forte (1 x 6 fluid ampoules)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31883223

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise training (CET) for 3 months, consisting of 30-min aerobic and 30-min resistance exercises three times a week for 12 weeks.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sedentary group (SG)
Number of subjects: 48
Study: 30509771

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg orally per day)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3966
Study: 30292279

Group type: EXPERIMENTAL
Intervention: CT texture analysis (specifically stdDeviation)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cross validation SVM classifiers
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Double-ROIs
Number of subjects: 69

Group type: COMPARATOR
Intervention: Subjective heterogeneity scores
Number of subjects: 69
Study: 26808474

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 371
Study: 24471979

Group type: EXPERIMENTAL
Intervention: MAL-PDT treatment
Number of subjects: 27
Study: 22902599

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg 8-hourly starting the afternoon before surgery until the fifth postoperative day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pregabalin and Placebo
Number of subjects: 80
Study: 20812790

Group type: EXPERIMENTAL
Intervention: Epoetin theta
Number of subjects: 270

Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 270
Study: 17939414

Group type: EXPERIMENTAL
Intervention: Septic shock with IAH
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Septic shock without IAH
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (postoperative patients) with IAH
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (postoperative patients) without IAH
Number of subjects: 46
Study: 16297748

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined sciatic and femoral nerve blocks with 40 mL of 0.375% bupivacaine
Number of subjects: 50
Study: 12239138

Group type: EXPERIMENTAL
Intervention: Epoetin (subcutaneous, 150 U/kg thrice weekly for a minimum of 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin (weekly, 40,000 U/wk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin (dose escalation if no response)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin (continuation beyond 6-8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin (titration once Hgb reaches 12 g/dL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy for anemic patients with hematologic malignancies
Number of subjects: 0
Study: 9705040

Group type: EXPERIMENTAL
Intervention: Diet LF (low fat)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet HP (high PUFA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet HM (high MUFA)
Number of subjects: 45
Study: 8557206

Group type: EXPERIMENTAL
Intervention: Comprehensive support program (psychosocial intervention including individual and family counseling, ad hoc counseling, support group participation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 30908627

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (relational reframes and focus on primary adaptive emotions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (interpretations, reassurances, and focus on rejecting anger toward parents)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (general encouragement of affect and focus on unmet attachment/identity needs)
Number of subjects: 30
Study: 27586686

Group type: EXPERIMENTAL
Intervention: Daily diary
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Weekly diary
Number of subjects: 241

Group type: COMPARATOR
Intervention: Automated feedback about risk behaviors
Number of subjects: 241

Group type: COMPARATOR
Intervention: Risk behavior engagement
Number of subjects: 241

Group type: COMPARATOR
Intervention: Substance use
Number of subjects: 241
Study: 26919180

Group type: EXPERIMENTAL
Intervention: Optimized adult oxygenator without integrated arterial filter (IAF)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Full adult oxygenator without integrated arterial filter (IAF)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Optimized adult oxygenator with integrated arterial filter (IAF)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Full adult oxygenator with integrated arterial filter (IAF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Optimized adult oxygenator without IAF
Number of subjects: 68

Group type: COMPARATOR
Intervention: Full adult oxygenator without IAF
Number of subjects: 68

Group type: COMPARATOR
Intervention: Optimized adult oxygenator with IAF
Number of subjects: 68

Group type: COMPARATOR
Intervention: Full adult oxygenator with IAF
Number of subjects: 68
Study: 25640050

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 213
Study: 24095239

Group type: EXPERIMENTAL
Intervention: Injection technique with traction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Injection technique without traction
Number of subjects: 70
Study: 21970555

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 40
Study: 18315590

Group type: EXPERIMENTAL
Intervention: Elemental diet (partial replacement of normal diet with elemental diet for 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (normal diet)
Number of subjects: 50
Study: 16441715

Group type: EXPERIMENTAL
Intervention: Single-sensor rate-responsive pacing with XL or MV sensors
Number of subjects: 105

Group type: COMPARATOR
Intervention: Dual-sensor rate-responsive pacing
Number of subjects: 105
Study: 14627933

Group type: EXPERIMENTAL
Intervention: Holistic wellness program (six half-day workshops over 3 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 10868823

Group type: EXPERIMENTAL
Intervention: Calendar blister pack (CBP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 9491842

Group type: EXPERIMENTAL
Intervention: High vancomycin trough serum levels (> 15 microg/mL)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Low vancomycin trough serum levels (< 15 microg/mL)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vancomycin therapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vancomycin failures
Number of subjects: 198
Study: 8236133

Group type: EXPERIMENTAL
Intervention: Impedance plethysmography (IPG) in symptomatic patients
Number of subjects: 363

Group type: COMPARATOR
Intervention: Impedance plethysmography (IPG) in asymptomatic patients
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Proximal DVT in symptomatic patients
Number of subjects: 363

Group type: COMPARATOR
Intervention: Proximal DVT in asymptomatic patients
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Mean Marder score in symptomatic patients
Number of subjects: 363

Group type: COMPARATOR
Intervention: Mean Marder score in asymptomatic patients
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Occlusive DVT in symptomatic patients
Number of subjects: 363

Group type: COMPARATOR
Intervention: Occlusive DVT in asymptomatic patients
Number of subjects: 363
Study: 2951802

Group type: EXPERIMENTAL
Intervention: Fenoterol 400 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms plus ipratropium bromide 80 micrograms (Duovent)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30317420

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite as a haemostatic agent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 30
Study: 28574153

Group type: EXPERIMENTAL
Intervention: High glycaemic index (≥65) with high proportion of carbohydrate (58% kcal)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI≤45) with low proportion of carbohydrate (40% kcal)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Low glycaemic index with high proportion of carbohydrate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: High glycaemic index with low proportion of carbohydrate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Reducing both glycaemic index and proportion of carbohydrates
Number of subjects: 159
Study: 25770420

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24054874

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (1.0×10(8) CFU, twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsule (twice daily)
Number of subjects: 40
Study: 21401942

Group type: EXPERIMENTAL
Intervention: Videoconference co‐located
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Webcast co‐located
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Videoconference dispersed
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Webcast dispersed
Number of subjects: 81